Buy Stocks Easy | About Us
May 8, 2021
Buy Stocks Easy | Online Stocks

TORC


Buy resTORbio, Inc. Stock (symbol: TORC) Easy Online

Company Name: resTORbio, Inc.

Symbol: TORC

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2018

TORC Current Share Price

Today's TORC ( resTORbio, Inc. ) opening price: $1.2400

Yesterday's TORC ( resTORbio, Inc. ) closing price: $1.2400

resTORbio, Inc. Stock ( symbol: TORC ) Price Chart since IPO (2018):

12 Months resTORbio, Inc. Stock ( symbol: TORC ) Price Chart

Popular Questions about resTORbio, Inc. Public Stock ( TORC )

A: resTORbio, Inc. stock symbol (also called stock or share ticker) is TORC

A: resTORbio, Inc. IPO (Initial Public Offering) took place on 2018

A: resTORbio, Inc.'s stock (TORC symbol) price at ther IPO (initial Public Offering) was $1.2400

Q: Is TORC stock worth buying at the moment?

A: The TORC stock performance since 2019 are rather disappointing. If you had bought 1 share of resTORbio, Inc. stock (symbol: TORC) at the beginning of 2019, at the opening share price of $8.8800, you would be left with exactly $1.2400 - which means a waste of your money and time. - SHOW ONLY IF equal or loose.

Buy resTORbio, Inc. Stock Easy Online

resTORbio, Inc. Stock Ticker Price Chart since IPO:





resTORbio, Inc. Stock Price Yesterday



 


resTORbio, Inc. Stock Price – Last Week




 


resTORbio, Inc. Stock Price – Last Month




 


resTORbio, Inc. Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            https://seekingalpha.com/article/4307806-restorbio-trading-less-half-net-cash-crash
                            

                                
ResTORbio Is Trading At Less Than Half Of Its Net Cash After Crash

                                
                                
ResTORbio Is Trading At Less Than Half Of Its Net Cash After Crash


                            

                        
                    

                


                            

                    


                        
                            https://247wallst.com/healthcare-business/2019/11/15/restorbio-becomes-next-biotech-implosion-and-other-indications-may-not-matter/
                            

                                
resTORbio Becomes Next Biotech Implosion, and Other Indications May Not Matter

                                
                                
There is a huge risk-reward factor in emerging pharmaceutical and b...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/02/1923890/0/en/resTORbio-Presents-New-Findings-on-RTB101-During-Late-Breaking-Session-at-IDWeek-2019.html
                            

                                
resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019

                                
                                
Analysis indicates RTB101 upregulates innate antiviral immunity to ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/23/1919127/0/en/resTORbio-to-Present-Findings-on-Investigational-TORC1-Inhibitor-RTB101-in-Late-Breaking-Session-at-IDWeek-2019.html
                            

                                
resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019

                                
                                
BOSTON, Sept.  23, 2019  (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasd...


                            

                        
                    

                


                            

                    


                        
                            https://seekingalpha.com/article/4280377-restorbio-strong-results-phase-2-makes-worth-look?source=feed_tag_long_ideas
                            

                                
resTORbio: Strong Results In Phase 2 Makes This Worth A Look

                                
                                
TORC has done tolerably well since IPO-ing last year, producing sol...


                            

                        
                    

                


                            

                    


                        
                            https://seekingalpha.com/article/4307806-restorbio-trading-less-half-net-cash-crash
                            

                                
ResTORbio Is Trading At Less Than Half Of Its Net Cash After Crash

                                
                                
ResTORbio Is Trading At Less Than Half Of Its Net Cash After Crash


                            

                        
                    

                


                            

                    


                        
                            https://247wallst.com/healthcare-business/2019/11/15/restorbio-becomes-next-biotech-implosion-and-other-indications-may-not-matter/
                            

                                
resTORbio Becomes Next Biotech Implosion, and Other Indications May Not Matter

                                
                                
There is a huge risk-reward factor in emerging pharmaceutical and b...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/02/1923890/0/en/resTORbio-Presents-New-Findings-on-RTB101-During-Late-Breaking-Session-at-IDWeek-2019.html
                            

                                
resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019

                                
                                
Analysis indicates RTB101 upregulates innate antiviral immunity to ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/23/1919127/0/en/resTORbio-to-Present-Findings-on-Investigational-TORC1-Inhibitor-RTB101-in-Late-Breaking-Session-at-IDWeek-2019.html
                            

                                
resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019

                                
                                
BOSTON, Sept.  23, 2019  (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasd...


                            

                        
                    

                


                            

                    


                        
                            https://seekingalpha.com/article/4280377-restorbio-strong-results-phase-2-makes-worth-look?source=feed_tag_long_ideas
                            

                                
resTORbio: Strong Results In Phase 2 Makes This Worth A Look

                                
                                
TORC has done tolerably well since IPO-ing last year, producing sol...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.